Sponsor Pipeline

Eidos Therapeutics, a BridgeBio company Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
2
Recruiting
3
Phase 3
2
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-30 NCT07695701
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis		 Recruitment opened
Active Trials by Phase
Phase 4
1
Phase 3
3
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07695701 Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Recruiting
Phase 3
NCT06563895 Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in… Amyloidosis Recruiting
NCT04988386 Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants Amyloid Cardiomyopathy, Transthyretin-Related Active, Not Recruiting
NCT07116473 To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With… Amyloidosis in Transthyretin (TTR) Not Yet Recruiting
Phase 2
NCT03536767 Open-Label Study of AG10 in Patients with Cardiomyopathy Amyloid Cardiomyopathy Active, Not Recruiting
Disease Areas
Amyloidosis (3) Heart Disease (2)
Get alerts when Eidos Therapeutics, a BridgeBio company's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free